ArticleNeuro-oncology2022

Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.

Mary Jane Lim-Fat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.